Antimicrobial Chemotherapy
Review
1 May 2024

An updated list of eumycetoma causative agents and their differences in grain formation and treatment response

Special Series: Fungi’s Most Wanted 

SUMMARY

In 2023, the World Health Organization designated eumycetoma causative agents as high-priority pathogens on its list of fungal priority pathogens. Despite this recognition, a comprehensive understanding of these causative agents is lacking, and potential variations in clinical manifestations or therapeutic responses remain unclear. In this review, 12,379 eumycetoma cases were reviewed. In total, 69 different fungal species were identified as causative agents. However, some were only identified once, and there was no supporting evidence that they were indeed present in the grain. Madurella mycetomatis was by far the most commonly reported fungal causative agent. In most studies, identification of the fungus at the species level was based on culture or histology, which was prone to misidentifications. The newly used molecular identification tools identified new causative agents. Clinically, no differences were reported in the appearance of the lesion, but variations in mycetoma grain formation and antifungal susceptibility were observed. Although attempts were made to explore the differences in clinical outcomes based on antifungal susceptibility, the lack of large clinical trials and the inclusion of surgery as standard treatment posed challenges in drawing definitive conclusions. Limited case series suggested that eumycetoma cases caused by Fusarium species were less responsive to treatment than those caused by Madurella mycetomatis. However, further research is imperative for a comprehensive understanding.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
WHO. 2016. WHA69.21: assessing the burden of mycetoma. WHO, Geneva.
2.
Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH. 2016. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 16:100–112.
3.
van de Sande W, Fahal A, Ahmed SA, Serrano JA, Bonifaz A, Zijlstra E, eumycetoma working group. 2018. Closing the mycetoma knowledge gap. Med Mycol 56:153–164.
4.
WHO. 2023. WHO fungal priority pathogens list to guide research, development and public health action
5.
van de Sande WWJ. 2013. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis 7:e2550.
6.
Oladele RO, Ly F, Sow D, Akinkugbe AO, Ocansey BK, Fahal AH, van de Sande WWJ. 2021. Mycetoma in West Africa. Trans R Soc Trop Med Hyg 115:328–336.
7.
Balabanoff VA. 1980. Mycetomas originated from South-East Bulgaria (author's transl). Ann Parasitol Hum Comp 55:605–613.
8.
Avram A. 1966. A study of mycetomas of rumania. Mycopathol Mycol Appl 28:1–15.
9.
Abbott P. 1956. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 50:11–24.
10.
Lynch JB. 1964. Mycetoma in the Sudan. Ann R Coll Surg Engl 35:319–340.
11.
Fahal AH, Sabaa AHA. 2010. Mycetoma in children in Sudan. Trans R Soc Trop Med Hyg 104:117–121.
12.
Fahal A, Mahgoub ES, El Hassan AM, Jacoub AO, Hassan D. 2015. Head and neck mycetoma: the mycetoma research centre experience. PLoS Negl Trop Dis 9:e0003587.
13.
Ahmed EA, Nour BYM, Abakar AD, Hamid S, Mohamadani AA, Daffalla M, Mahmoud M, Altayb HN, Desnos-Ollivier M, de Hoog S, Ahmed SA. 2020. The genus Madurella: molecular identification and epidemiology in Sudan. PLoS Negl Trop Dis 14:e0008420.
14.
Mohamed ESW, Bakhiet SM, El Nour M, Suliman SH, El Amin HM, Fahal AH. 2021. Surgery in mycetoma-endemic villages: unique experience. Trans R Soc Trop Med Hyg 115:320–323.
15.
Hassan R, Deribe K, Fahal AH, Newport M, Bakhiet S. 2021. Clinical epidemiological characteristics of mycetoma in eastern Sennar locality, Sennar state, Sudan. PLoS Negl Trop Dis 15:e0009847.
16.
Siddig EE, Ahmed A, Hassan OB, Bakhiet SM, Verbon A, Fahal AH, van de Sande WWJ. 2023. Using a Madurella mycetomatis-specific PCR on grains obtained via non-invasive fine-needle aspirated material is more accurate than cytology. Mycoses 66:477–482.
17.
Abate DA, Ayele MH, Mohammed AB. 2021. Subcutaneous mycoses in Ethiopia: a retrospective study in a single dermatology center. Trans R Soc Trop Med Hyg 115:1468–1470.
18.
Tilahun Zewdu F, Getahun Abdela S, Takarinda KC, Kamau EM, Van Griensven J, Van Henten S. 2022. Mycetoma patients in Ethiopia: case series from Boru Meda hospital. J Infect Dev Ctries 16:41S–44S.
19.
Enbiale W, Bekele A, Manaye N, Seife F, Kebede Z, Gebremeskel F, van Griensven J. 2023. Subcutaneous mycoses: endemic but neglected among the neglected tropical diseases in Ethiopia. PLoS Negl Trop Dis 17:e0011363.
20.
Wilson AM. 1965. The aetiology of mycetoma in Uganda compared with other African countries. East Afr Med J 42:182–190.
21.
Kwizera R, Bongomin F, Meya DB, Denning DW, Fahal AH, Lukande R. 2020. Mycetoma in Uganda: a neglected tropical disease. PLoS Negl Trop Dis 14:e0008240.
22.
Vanbreuseghem R. 1958. Epidemiologie et therapeutique des pieds de Madura au Congo belge. Bull Soc Pathol Exot 51:759–814.
23.
Destombes P, Mariat F, Rosati L, Segretain G. 1977. Mycetoma in Somalia - results of a survey done from 1959 to 1964. Acta Trop 34:355–373.
24.
Destombes P, Du Tour J, Marquet J, Mariat F, Segretain G. 1958. Les mycétomes en Côte Française des Somalis. Bull Soc Pathol Exot 51:575–581.
25.
Orio J, Destombes P, Mariat F, Segretain G. 1963. Mycetoma in the French Somali coast. Review of 50 cases observed between 1954 and 1962. Bull Soc Pathol Exot Filiales 56:161–173.
26.
Colom MF, Ferrer C, Ekai JL, Ferrández D, Ramírez L, Gómez-Sánchez N, Leting S, Hernández C. 2023. First report on mycetoma in Turkana County-North-Western Kenya. PLoS Negl Trop Dis 17:e0011327.
27.
Mavura D, Chapa P, Sabushimike D, Kini L, Hay R. 2021. Mycetoma in Moshi, Tanzania. Trans R Soc Trop Med Hyg 115:340–342.
28.
Agarwal SC, Mathur DR. 1985. Mycetoma in northern Nigeria. Trop Geogr Med 37:133–135.
29.
Mahe A, Develoux M, Lienhardt C, Keita S, Bobin P. 1996. Mycetomas in Mali: causative agents and geographic distribution. Am J Trop Med Hyg 54:77–79.
30.
Traore T, Toure L, Diassana M, Niang M, Ballo E, S Coulibaly B, Hans-Moevi A. 2021. Prise en charge medico-chirurgicale des mycetomes a l'hopital Somine Dolo de Mopti (Mali). Med Trop Sante Int 1:mtsi.2021.170.
31.
Philippon M, Larroque D, Ravisse P. 1992. Mycetoma in Mauritania: species found, epidemiologic characteristics and country distribution. Bull Soc Pathol Exot 85:107–114.
32.
Kébé M, Ba O, Mohamed Abderahmane MA, Mohamed Baba ND, Ball M, Fahal A. 2021. A study of 87 mycetoma patients seen at three health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg 115:315–319.
33.
Bourrel P, Cerutti J, Disy P, Olivier R. 1974. Les mycetomas propos de 64 observations. Méd Trop 34:221–247.
34.
Klueken N, Camain R, Baylet M, Basset A. 1965. Epidemiology, clinical aspects and treatment of mycetoma in Western Africa. Hautarzt 16:1–6.
35.
Rey M, Baylet R, Camain R. 1962. Donnees actuelles sur les mycetomes. A propos de 214 cas africains. Ann Derm Syph 89:511–527.
36.
Ndiaye B, Develoux M, Langlade MA, Kane A. 1994. Actinomycotic mycetoma. Apropos of 27 cases in Dakar; medical treatment with cotrimoxazole. Ann Dermatol Venereol 121:161–165.
37.
Dieng MT, Niang SO, Diop B, Ndiaye B. 2005. Actinomycetomas in Senegal: study of 90 cases. Bull Soc Pathol Exot 98:18–20.
38.
Dieng MT, Sy MH, Diop BM, Niang SO, Ndiaye B. 2003. Mycetoma: 130 cases. Ann Dermatol Venereol 130:16–19.
39.
Sarr L, Niane MM, Diémé CB, Diatta BA, Coulibaly NF, Dembélé B, Diouf AB, Kinkpé CAV, Sané AD, Ndiaye A, Seye SIL. 2016. Chirurgie des mycetomes fongiques a grain noir. A propos de 44 patients pris en charge a l'Hopital Aristide le Dantec de Dakar (Senegal) de decembre 2008 a mars 2013. Bull Soc Pathol Exot 109:8–12.
40.
Diadie S, Ndiaye M, Diop K, Diongue K, Diouf J, Sarr M, Sarr L, Ly F, Dieng MT, Niang SO. 2022. Extrapodal mycetomas in Senegal: epidemiologica, clinical and etiological study of 82 cases diagnoses from 2000 to 2020. Med Trop Sante Int 2:1–8.
41.
Badiane AS, Ndiaye M, Diongue K, Diallo MA, Seck MC, Ndiaye D. 2020. Geographical distribution of mycetoma cases in Senegal over a period of 18 years. Mycoses 63:250–256.
42.
Sow D, Ndiaye M, Sarr L, Kanté MD, Ly F, Dioussé P, Faye BT, Gaye AM, Sokhna C, Ranque S, Faye B. 2020. Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018. PLoS One 15:e0231871.
43.
Develoux M, Audoin J, Treguer J, Vetter JM, Warter A, Cenac A. 1988. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg 38:386–390.
44.
Gamet A, Brottes H, Essomba R. 1964. New cases of mycetoma detected in Cameroun. Bull Soc Pathol Exot Filiales 57:1191–1195.
45.
Pitche P, Napo-Koura G, Kpodzro K, Tchangaï-Wallam K. 1999. Les mycetomes au Togo: aspects épidémiologiques et étiologiques de cas histologiquement diagnostiqués. Med Afr Noire 46:322–325.
46.
Darré T, Saka B, Mouhari-Toure A, Tchaou M, Dorkenoo AM, Doh K, Walla A, Amégbor K, Pitché VP, Napo-Koura G. 2018. Mycetoma in the togolese: an update from a single-center experience. Mycopathologia 183:961–965.
47.
Coulanges P, Vicens R, Rakotonirina-Randriambeloma PJ. 1987. Mycetomas in Madagascar (apropos of 142 cases seen in the laboratory of anatomical pathology of the Pasteur Institute of Madagascar from 1954 to 1984. Arch Inst Pasteur Madagascar 53:35–42.
48.
Ahmed SA, El-Sobky TA, de Hoog S, Zaki SM, Taha M. 2023. A scoping review of mycetoma profile in Egypt: revisiting the global Endemicity map. Trans R Soc Trop Med Hyg 117:1–11.
49.
Daoud M, Ezzine Sebai N, Badri T, Mokhtar I, Fazza B, Kamoun MR. 2005. Mycetoma: retrospective study of 13 cases in Tunisia. Acta Dermatovenerol Alp Panonica Adriat 14:153–156.
50.
Elgallali N, El Euch D, Cheikhrouhou R, Belhadj S, Chelly I, Chaker E, Ben Osman A. 2010. Mycetoma in Tunisia: a 15-case series. Med Trop (Mars) 70:269–273.
51.
Aounallah A, Boussofara L, Ben Saïd Z, Ghariani N, Saidi W, Denguezli M, Belajouza C, Nouira R. 2013. Analyse d'une serie tunisienne de 18 cas de mycetomes a l'hopital de Sousse (1974-2010). Bull Soc Pathol Exot 106:5–8.
52.
Marc S, Meziane M, Hamada S, Hassam B, Benzekri L. 2011. Clinical and epidemiological features of mycetoma in Morocco. Med Mal Infect 41:163–164.
53.
Messoudi A, Fnini S, El Andaloussi Y, Charafeddine A, Marouane S, Ouarab M, Largab A. 2013. Madura foot: a rare pathology in Morocco (about 15 cases). Bull Soc Pathol Exot 106:9–12.
54.
Tazi S, Konzi KM-E, Chachi EM, Lyagoubi M, Aoufi S. 2019. Epidemiological profile of eumycetomas in Rabat, Morocco, over 40 years. J Mycol Med 29:356–360.
55.
Khatri ML, Al Kubati SAS, Gaffer IA, Majeed SMA. 2022. Mycetoma in North-Western Yemen: clinico-epidemiological and histopathological study. Indian J Dermatol Venereol Leprol 88:615–622.
56.
Khatri ML, Al-Halali HM, Fouad Khalid M, Saif SA, Vyas MCR. 2002. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol 41:586–593.
57.
Yu AM, Zhao S, Nie LY. 1993. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 48:812–817.
58.
Bendl BJ, Mackey D, Al-Saati F, Sheth KV, Ofole SN, Bailey TM. 1987. Mycetoma in Saudi Arabia. J Trop Med Hyg 90:51–59.
59.
Mufti ST, Aljhdali H. 2015. Mycetoma at a tertiary care hospital in Saudi Arabia: correlation of histopathological and clinical findings. Asian Pac J Trop Biomed 5:331–336.
60.
Venugopal PV, Venugopal TV. 1990. Leptosphaeria tompkinsii mycetoma. Int J Dermatol 29:432–433.
61.
Hashemi SJ, Nasrollahi A, Guerami M, Daei R, Pakshir K, Zibafar A. 2008. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 1:77–81.
62.
Bassiri-Jahromi S. 2014. Mycetoma in Iran: causative agents and geographic distribution. Indian J Dermatol 59:529.
63.
Mallick YA, Yaqoob N. 2021. Clinical and epidemiological profile of mycetoma patients from a tertiary care center in Karachi, Pakistan. An Bras Dermatol 96:617–619.
64.
Zeeshan M, Fatima S, Farooqi J, Jabeen K, Ahmed A, Haq A, Arif MO, Zafar A. 2022. Reporting of mycetoma cases from skin and soft tissue biopsies over a period of ten years: a single center report and literature review from Pakistan. PLoS Negl Trop Dis 16:e0010607.
65.
Maiti PK, Ray A, Bandyopadhyay S. 2002. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 7:788–792.
66.
Padhi S, Uppin SG, Uppin MS, Umabala P, Challa S, Laxmi V, Prasad VBN. 2010. Mycetoma in South India: retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: Neoscytalidium dimidiatum and Aspergillus flavus. Int J Dermatol 49:1289–1296.
67.
Dubey N, Capoor MR, Hasan AS, Gupta A, Ramesh V, Sharma S, Singh A, Rudramurthy SM, Chakrabarti A. 2019. Epidemiological profile and spectrum of neglected tropical disease eumycetoma from Dehli, North India. Epidemiol Infect 147:e294.
68.
Chakraborti A, Singh K. 1998. Mycetoma in Chandigarh and surrounding areas. Indian J Med Microbiol 16:64–65.
69.
Chouhan SS, Agarwal S. 1961. Histological diagnosis of mycetoma – a clinical study of 24 cases. Indian J Med Res 57:71–77.
70.
Venugopal TV, Venugopal PV, Paramasivan CN, Shetty BMV, Subramanian S. 1977. Mycetomas in Madras. Med Mycol 15:17–22.
71.
Reddy C, Samdareshwar B, Rao AP, Reddy SS. 1972. Mycetoma – histological diagnosis of causal agents in 50 cases. Indian J Med Sci 26:733–736.
72.
Talwar P, Sehgal SC. 1979. Mycetomas in North India. Sabouraudia 17:287–291.
73.
Klokke AH, Swamidasan G, Anguli R, Verghese A. 1968. The causal agents of mycetoma in South India. Trans R Soc Trop Med Hyg 62:509–516.
74.
Bakshi R, Mathur DR. 2008. Incidence and changing pattern of mycetoma in Western Rajasthan. Indian J Pathol Microbiol 51:154–155.
75.
Mathur DR, Joshi KR, Mathur A. 1979. An etiological and pathological study of mycetoma in Western Rajasthan. Curr Med Pract 23:151–161.
76.
Joshi KR, Sanghvi A, Vyas MC, Sharma JC. 1987. Etiology & distribution of mycetoma in Rajasthan, India. Indian J Med Res 85:694–698.
77.
Kotrajaras R. 1981. Mycetoma, a review of seventeen cases seen at the institute of dermatology. J Dermatol 8:133–137.
78.
Wang R, Yao X, Li R. 2019. Mycetoma in China: a case report and review of the literature. Mycopathologia 184:327–334.
79.
Negroni R. 1974. Contribucion al estudio de los micetomas en. la Republica Argentina. Med Cut ILA 2:353–362.
80.
Negroni R, López Daneri G, Arechavala A, Bianchi MH, Robles AM. 2006. Clinical and microbiological study of mycetomas at the Muniz hospital of Buenos Aires between 1989 and 2004. Rev Argent Microbiol 38:13–18.
81.
Biagini RE, Museu A, Martinez T, Salvador M. 1977. Micetomas en la provincia de Salta. Archivos Argentinos Dermat 4:217–226.
82.
Biagini RE, Martínez TE, Museli A, Sarmiento Villa H. 1983. Mycetoma in northern Argentina. Med Cutan Ibero Lat Am 11:431–436.
83.
Niño FL, Freire RS. 1966. Maduromycotic mycetoma in the province of Chaco (Argentina). Mycopathol Mycol Appl 28:95–96.
84.
Rojas OC, León-Cachón RBR, Moreno-Treviño M, González GM. 2017. Molecular identification of unusual mycetoma agents isolated from patients in Venezuela. Mycoses 60:129–135.
85.
Castro LG, Belda Júnior W, Salebian A, Cucé LC. 1993. Mycetoma: a retrospective study of 41 cases seen in Sao Paulo, Brazil, from 1978 to 1989. Mycoses 36:89–95.
86.
Lacaz CS. 1981. Distribuicao geografica dos micetomas no Brasil. / Geographic distribution of mycetoma in Brazil. An Bras Dermatol 56:167–172.
87.
Lavalle P. 1966. New data on the etiology of mycetoma in Mexico and on its pathogenesis. Gac Med Mex 96:545–574.
88.
López Martínez R, Méndez Tovar LJ, Lavalle P, Welsh O, Saúl A, Macotela Ruíz E. 1992. Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac Med Mex 128:477–481.
89.
Buot G, Lavalle P, Mariat F, Suchil P. 1987. Epidemiologic study of mycetomas in Mexico. Apropos of 502 cases. Bull Soc Pathol Exot Filiales 80:329–339.
90.
Lopez-Martinez R, Mendez-Tovar LJ, Bonifaz A, Arenas R, Mayorga J, Welsh O, Vera-Cabrera L, Padilla-Desgarennes MC, Contreras Perez C, Chavez G, Estrada R, Hernandez-Hernandez F, Manzano-Gayosso P. 2013. Actualizacion de la epidemiologia del micetoma en Mexico. Revision de 3,933 casos. Gac Med Mex 149:586–592.
91.
Bonifaz A, Tirado-Sánchez A, Araiza J, Treviño-Rangel R, González GM. 2021. Deep mycoses and pseudomycoses of the foot: a single-center retrospective study of 160 cases, in a tertiary-care center in Mexico. The Foot 46:101770.
92.
Roberto E, Guadalupe CL, Guadalupe EC, Hay R. 2021. Mycetoma and the community dermatology program, Mexico. Trans R Soc Trop Med Hyg 115:383–386.
93.
Cárdenas-de la Garza JA, Welsh O, Cuéllar-Barboza A, Suarez-Sánchez KP, De la Cruz-Valadez E, Cruz-Gómez LG, Gallardo-Rocha A, Ocampo-Candiani J, Vera-Cabrera L. 2020. Clinical characteristics and treatment of actinomycetoma in northeast Mexico: a case series. PLoS Negl Trop Dis 14:e0008123.
94.
Ahmed SA, De Hoog GS, Van de Sande WWJ. 2019. Fungi causing eumycotic mycetoma, p 2261–2277. In Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW (ed), Manual of clinical microbiology, 12th ed. Vol. 2. ASM Press, Washington, DC.
95.
Borman AM, Desnos-Ollivier M, Campbell CK, Bridge PD, Dannaoui E, Johnson EM. 2016. Novel taxa associated with human fungal black-grain mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov. J Clin Microbiol 54:1738–1745.
96.
Fraser M, Borman AM, Johnson EM. 2017. Rapid and robust identification of the agents of black-grain mycetoma by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 55:2521–2528.
97.
Desnos-Ollivier M, Bretagne S, Dromer F, Lortholary O, Dannaoui E. 2006. Molecular identification of black-grain mycetoma agents. J Clin Microbiol 44:3517–3523.
98.
Borman AM, Desnos-Ollivier M, Miles S-J, Linton CJ, Campbell CK, Bridge PD, Dannaoui E, Johnson EM. 2009. Molecular characterisation of the Madurella grisea complex reveals at least three new taxa associated with human mycetomas. abstr ISHAM 2009, Tokyo.
99.
Siddig EE, Nyuykonge B, Mhmoud NA, Abdallah OB, Bahar MEN, Ahmed ES, Nyaoke B, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ. 2023. Comparing the performance of the common used eumycetoma diagnostic tests. Mycoses 66:420–429.
100.
N’Diaye B, Develoux M, Dieng MT, Ndiaye PD, Ndir O. 1995. Les mycétomes à la Clinique Dermatologique de Dakar (Sénégal) : aspects épidémiologiques: à propos de 111 cas. Med Afr Noire 42:207–212.
101.
N’diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R. 2006. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 45:154–157.
102.
Ndiaye D, Ndiaye M, Sène PD, Diouf MN, Diallo M, Faye B, Sakho MG, Ndiaye JL, Tine R, Kane A, Ndir O. 2011. Mycétomes diagnostiqués au Sénégal de 2008 à 2010. J Mycol Med 21:173–181.
103.
Venucopal PV, Venugopal TV, Laing WN, Humaidan YAl, Namnyak SS, Jama AAAl, Elbashier AM. 1990. Black grain mycetoma caused by Madurella grisea in Saudi Arabia . Int J Dermatol 29:434–435.
104.
Estrada-Castañón R, Estrada-Chávez G, Chávez-López M de G. 2019. Diagnosis and management of fungal neglected tropical diseases in community settings-mycetoma and sporotrichosis. TropicalMed 4:81.
105.
Baylet R, Camain R, Chabal J, Izarn R. 1968. Nouvelle contribution a l'etude des mycetomes au Senegal. Neotestudina rosatii. Pyrenochaeta romeroi. Aspergillus nidulans. Bull Soc Med Afr Noire Lang Fr 13:311–313.
106.
Kaur M, Singla N, Bhalla M, Kundu R, Gulati N, Chander J. 2021. Aspergillus candidus eumycetoma with review of literature. J Med Mycol 31:101135.
107.
Ahmed SA, Abbas MA, Jouvion G, Al-Hatmi AMS, de Hoog GS, Kolecka A, Mahgoub ES. 2015. Seventeen years of subcutaneous infection by Aspergillus flavus; eumycetoma confirmed by immunohistochemistry. Mycoses 58:728–734.
108.
Kamali Sarvestani H, Ahmadi B, Gerami Shoar M, Getso M, Rafat Z, Mahmoudi S, Khansari M, Salahshour F, Fatahi L, Salehi M, Ansari S. 2022. Mycetoma due to Aspergillus flavus in a diabetic patient: case report and literature review. IDCases 29:e01585.
109.
Witzig RS, Greer DL, Hyslop NE. 1996. Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole. J Med Vet Mycol 34:133–137.
110.
Veraldi S, Grancini A, Venegoni L, Merlo V, Guanziroli E, Menicanit C, Nazzaro G, Tortorano A. 2016. Mycetoma caused by Aspergillus nidulans. Acta Derm Venereol 96:118–119.
111.
Prasanna S, Grover N, Bhatt P, Sahni AK. 2016. A case of Aspergillus nidulans causing white granule mycetoma. Med J Armed Forces India 72:88–90.
112.
Joshi KR, Mathur DR, Sharma JC, Vyas MC, Sanghvi A. 1985. Mycetoma caused by Aspergillus nidulans in India. J Trop Med Hyg 88:41–44.
113.
Verma R, Vasudevan B, Sahni AK, Vijendran P, Neema S, Kharayat V. 2015. First reported case of Aspergillus nidulans eumycetoma in a sporotrichoid distribution. Int J Dermatol 54:74–77.
114.
Baylet R, Basset A. 1968. Aspergillus nidulans, agent of mycetoma. Bull Soc Pathol Exot Filiales 61:359–365.
115.
Vera-Cabrera L, Cardenas-de la Garza JA, Cuellar-Barboza A, Gallardo-Rocha A, Molina-Torres CA, Escalante-Fuentes W, Ocampo-Candiani J. 2021. Case report: Coral reef pathogen Aspergillus sydowii causing black grain mycetoma: a review. Am J Trop Med Hyg 104:871–873.
116.
Werlinger KD, Yen Moore A. 2005. Eumycotic mycetoma caused by Cladophialophora bantiana in a patient with systemic lupus erythematosus. J Am Acad Dermatol 52:S114–S117.
117.
Bonifaz A, De Hoog S, McGinnis MR, Saúl A, Rodríguez-Cortés O, Araiza J, Cruz M, Mercadillo P. 2009. Eumycetoma caused by Cladophialophora bantiana successfully treated with itraconazole. Med Mycol 47:111–114.
118.
Mahgoub E. 1969. Corynespora cassiicola, a new agent of maduromycetoma. J Trop Med Hyg 72:218–221.
119.
Bridges CH. 1957. Maduromycotic mycetomas in animals; Curvularia geniculata as an etiologic agent. Am J Pathol 33:411–427.
120.
Boomker J, Coetzer JA, Scott DB. 1977. Black grain mycetoma (maduromycosis) in horses. Onderstepoort J Vet Res 44:249–251.
121.
Clark FD, Jones LP, Panigrahy B. 1986. Mycetoma in a grand Eclectus (Eclectus roratus roratus) parrot. Avian Dis 30:441–443.
122.
Gunathilake R, Perera P, Sirimanna G. 2014. Curvularia lunata: a rare cause of black-grain eumycetoma. J Mycol Med 24:158–160.
123.
Garg A, Sujatha S, Garg J, Parija SC, Thappa DM. 2008. Eumycetoma due to Curvularia lunata. Indian J Dermatol Venereol Leprol 74:515–516.
124.
Iriart X, Binois R, Fior A, Blanchet D, Berry A, Cassaing S, Amazan E, Papot E, Carme B, Aznar C, Couppié P. 2011. Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans. Clin Microbiol Infect 17:1492–1494.
125.
Crabol Y, Poiree S, Bougnoux M-E, Maunoury C, Barete S, Zeller V, Arvieux C, Pineau S, Amazzough K, Lecuit M, Lanternier F, Lortholary O, French Mycosis Study Group. 2014. Last generation triazoles for imported eumycetoma in eleven consecutive adults. PLoS Negl Trop Dis 8:e3232.
126.
Severo LC, Vetoratto G, Oliveira F de M, Londero AT. 1999. Eumycetoma by Madurella grisea. Report of the first case observed in the Southern Brazilian region. Rev Inst Med Trop S Paulo 41:139–142.
127.
Neumeister B, Zollner TM, Krieger D, Sterry W, Marre R. 1995. Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses 38:271–276.
128.
Hemashettar BM, Patil CS, Nagalotimath SJ, Thammayya A. 1986. Mycetoma due to Exophiala jeanselmei (a case report with description of the fungus). Indian J Pathol Microbiol 29:75–78.
129.
Thammayya A, Sanyal M. 1980. Exophiala jeanselmei causing mycetoma pedis in India. Med Mycol 18:91–95.
130.
Badali H, Najafzadeh MJ, van Esbroeck M, van den Enden E, Tarazooie B, Meis JFGM, de Hoog GS. 2010. The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Med Mycol 48:318–327.
131.
Desoubeaux G, Millon A, Freychet B, de Muret A, Garcia-Hermoso D, Bailly E, Rosset P, Chandenier J, Bernard L. 2013. Eumycetoma of the foot caused by Exophiala jeanselmei in a Guinean woman. J Mycol Med 23:168–175.
132.
Capoor MR, Khanna G, Nair D, Hasan A, Deb M, Aggarwal P. 2007. Eumycetoma pedis due to Exophiala jeanselmei. Indian J Med Microbiol 25:155–157.
133.
Al-Tawfiq JA, Amr SS. 2009. Madura leg due to Exophiala jeanselmei successfully treated with surgery and itraconazole therapy. Med Mycol 47:648–652.
134.
Pattanaprichakul P, Bunyaratavej S, Leeyaphan C, Sitthinamsuwan P, Sudhadham M, Muanprasart C, Feng P, Badali H, de Hoog GS. 2013. An unusual case of eumycetoma caused by Exophiala jeanselmei after a sea urchin injury. Mycoses 56:491–494.
135.
Santona A, Mhmoud NA, Siddig EE, Deligios M, Fiamma M, Bakhiet SM, Barac A, Paglietti B, Rubino S, Fahal AH. 2021. Metagenomics of black grains: new highlights in the understanding of eumycetoma. Trans R Soc Trop Med Hyg 115:307–314.
136.
Olenski M, Halliday C, Gullifer J, Martinez E, Crowe A, Sheorey H, Darby J. 2021. A case of trauma-induced Falciformispora lignatilis eumycetoma in a renal transplant recipient. TropicalMed 6:144.
137.
Cartwright KE, Clark TW, Hussain AM, Wiselka M, Borman A, Johnson EM. 2011. Eumycetoma of the hand caused by Leptosphaeria tompkinsii and refractory to medical therapy with voriconazole. Mycopathologia 172:311–315.
138.
Machmachi H, Godineau N, Develoux M, Bretagne S, Bazeli A, Amsellem D, Desnos-Ollivier M, Poirat JB. 2011. Black grain mycetoma caused by Leptosphaeria tompkinsii. Med Mycol 49:186–189.
139.
Welfringer A, Parache RM. 1978. The role of histopathology in the diagnosis of mycetomas. Two cases of maduromycosis. Actinomadura pelletieri and Leptosphaeria tompkinsii (author’s transl). Arch Anat Cytol Pathol 26:50–58.
140.
Siddig EE, Ahmed A, Eltigani HF, Bakhiet SM, van de Sande WWJ, Fahal AH. 2023. The first case of Fusarium falciforme eumycetoma in Sudan and an extensive literature review about treatment worldwide. J Fungi 9:730.
141.
Bonifaz A, Saldaña M, Araiza J, Mercadillo P, Tirado-Sánchez A. 2017. Two simultaneous mycetomas caused by Fusarium verticillioides and Madurella mycetomatis. Rev Inst Med Trop Sao Paulo 59:e55.
142.
Martínez López D, Pérez Blasco A, García Ferrer L, Camarena JJ, González R, Rodrigo Perez JL. 2022. Eumicetomas por Fusarium oxysporum y Madurella mycetomatis. Descripcion de dos casos y revision de la bibliografia. Rev Esp Quimioter 35:566–569.
143.
Correia C, Ferreira J, Soares-de-Almeida L, Filipe P. 2022. An unusual cause of eumycetoma - Fusarium solani keratoplasticum. Actas Dermo-Sifiliográficas 113:899.
144.
Das L, Dahiya D, Gupta K, Prakash M, Malhotra B, Rastogi A, Choudhary H, Rudramurthy SM, Dutta P. 2021. Eumycetoma of the foot due to Fusarium solani in a person with diabetes mellitus: report of a case and review of literature. Mycopathologia 186:277–288.
145.
Prinja A, Roberts C, Doherty T, Oddy MJ. 2014. An unusual cause of an ankle mass. BMJ Case Rep 2014:bcr2014204253.
146.
Yera H, Bougnoux ME, Jeanrot C, Baixench MT, De Pinieux G, Dupouy-Camet J. 2003. Mycetoma of the foot caused by Fusarium solani: identification of the etiologic agent by DNA sequencing . J Clin Microbiol 41:1805–1808.
147.
Salas-Coronas J, Cabezas-Fernández T, Martínez-Lage MJV, Villarejo-Ordóñez A. 2011. Mycetoma caused by Fusarium solani. Rev Clin Esp 211:e16–e18.
148.
Tomimori-Yamashita J, Ogawa MM, Hirata SH, Fischman O, Michalany NS, Yamashita HK, Alchorne M. 2002. Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report. Mycopathologia 153:11–14.
149.
Malisiewicz B, Uhrlaß S, Nenoff P, Schöfer H. 2019. Eumyzetom durch Fusarium chlamydosporum: Fallbericht und Literaturubersicht. Hautarzt 70:612–617.
150.
Campos-Macías P, Arenas-Guzmán R, Hernández-Hernández F. 2013. Fusarium subglutinans: a new eumycetoma agent. Med Mycol Case Rep 2:128–131.
151.
Zoutman DE, Sigler L. 1991. Mycetoma of the foot caused by cylindrocarpon destructans. J Clin Microbiol 29:1855–1859.
152.
Konings M, Gerrits van den Ende B, Raats MWJ, Fahal AH, van de Sande WWJ, Hagen F. 2024. Complete genome sequence of the itraconazole decreased susceptible Madurella fahalii type-strain CBS 129176. Mycopathologia 189:6.
153.
Hallur V, Sirka CS, Sable M, Sethy M, Bag N, Sahu S, Sahoo M, Shivaprakash MR, Das M. 2024. A novel report of mycetoma with spinal spread due to Madurella fahalli from India. Indian J Med Microbiol 48:100523.
154.
de Hoog GS, van Diepeningen AD, Mahgoub E-S, van de Sande WWJ. 2012. New species of Madurella, causative agents of black-grain mycetoma. J Clin Microbiol 50:988–994.
155.
Borjian Boroujeni Z, Hashemi SJ, Daie Ghazvini R, Khodavaisy S, Zareei M, Hosseinpour L, Ardi P, Shokri M. 2019. Recurrent eumycetoma caused by novel species Madurella pseudomycetomatis: a case report. Med Mycol Case Rep 26:13–15.
156.
Yan J, Deng J, Zhou CJ, Zhong BY, Hao F. 2010. Phenotypic and molecular characterization of Madurella pseudomycetomatis sp. nov., a novel opportunistic fungus possibly causing black-grain mycetoma . J Clin Microbiol 48:251–257.
157.
Mhmoud NA, Siddig EE, Nyuykonge B, Bakhiet SM, van de Sande WWJ, Fahal AH. 2021. Mycetoma caused by Microascus gracilis: a novel agent of human eumycetoma in Sudan . Trans R Soc Trop Med Hyg 115:426–430.
158.
Teo TSP, Crawford LC, Pilch WT, Carney B, Solanki N, Kidd SE, Warner MS. 2021. Mycetoma caused by Microsporum canis in a patient with renal transplant: a case report and review of the literature . Transplant Infectious Dis 23:e13516.
159.
Chiapello LS, Dib MD, Nuncira CT, Nardelli L, Vullo C, Collino C, Abiega C, Cortes PR, Spesso MF, Masih DT. 2011. Mycetoma of the scalp due to Microsporum canis: hystopathologic, mycologic, and immunogenetic features in a 6-year-old girl. Diagn Microbiol Infect Dis 70:145–149.
160.
Kramer SC, Ryan M, Bourbeau P, Tyler WB, Elston DM. 2006. Fontana-positive grains in mycetoma caused by Microsporum canis. Pediatr Dermatol 23:473–475.
161.
Vezon G, Desbois N, Boisseau-Garsaud AM, Helenon R, Jouannelle A, Saint-Cyr I, Cales-Quist D. 2000. Microsporum canis mycetoma of the scalp. Ann Dermatol Venereol 127:729–731.
162.
de Vries GA, de Hoog GS, de Bruyn HP. 1984. Phialophora cyanescens sp. nov. with phaeosclera-like synanamorph, causing white-grain mycetoma in man. Antonie van Leeuwenhoek 50:149–153.
163.
Segretain G, Destombes P. 1961. Description of a new agent for maduromycosis, Neotestudina rosatii, n. gen., n. sp., isolated in Africa. C R Hebd Seances Acad Sci 253:2577–2579.
164.
Ahmed SA, González GM, Tirado-Sánchez A, Moreno-López LM, de Hoog S, Bonifaz A. 2018. Nigrograna mackinnonii, not Trematosphaeria grisea (syn., Madurella grisea), is the main agent of black grain eumycetoma in Latin America. J Clin Microbiol 56:e01723-17.
165.
Zimmer F, Kellner N, Nenoff P, Lübbert C. 2023. Eumycetoma caused by Biatriospora mackinnonii in a young pregnant woman from Somalia. Int J Infect Dis 128:1–2.
166.
Criado PR, Belda Junior W, da Matta VLR. 2021. First report of cutaneous mycetoma by Paecilomyces variotii and the successful treatment with combined itraconazole and terbinafine along with resection surgeries. Australas J Dermatol 62:e397–e399.
167.
Hemashettar BM, Siddaramappa B, Munjunathaswamy BS, Pangi AS, Pattan J, Andrade AT, Padhye AA, Mostert L, Summerbell RC. 2006. Phaeoacremonium krajdenii, a cause of white grain eumycetoma. J Clin Microbiol 44:4619–4622.
168.
Aguilar-Donis A, Torres-Guerrero E, Arenas-Guzmán R, Hernández-Hernández F, López-García L, Criales-Vera S, Teliz-Meneses MA. 2011. Mycetoma caused by Phaeoacremonium parasiticum--a case confirmed with B-tubulin sequence analysis. Mycoses 54:e615–8.
169.
Turiansky GW, Benson PM, Sperling LC, Sau P, Salkin IF, McGinnis MR, James WD. 1995. Phialophora verrucosa: a new cause of mycetoma. J Am Acad Dermatol 32:311–315.
170.
Mhmoud NA, Ahmed SA, Fahal AH, de Hoog GS, Gerrits van den Ende AHG, van de Sande WWJ. 2012. Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains. J Clin Microbiol 50:2987–2994.
171.
Namba HD, Umemura H, Asagoe K. 2017. Eumycetoma caused by Trichophyton species successfully treated with terbinafine and surgery. J Dermatol 44:e97–e98.
172.
Koshi G, Padhye AA, Ajello L, Chandler FW. 1979. Acremonium recifei as an agent of mycetoma in India. Am J Trop Med Hyg 28:692–696.
173.
Ahmed AO, van Vianen W, ten Kate MT, van de Sande WWJ, van Belkum A, Fahal AH, Verbrugh HA, Bakker-Woudenberg IAJM. 2003. A murine model of Madurella mycetomatis eumycetoma. FEMS Immunol Med Microbiol 37:29–36.
174.
Kloezen W, van Helvert-van Poppel M, Fahal AH, van de Sande WWJ. 2015. A Madurella mycetomatis grain model in Galleria mellonella larvae. PLoS Negl Trop Dis 9:e0003926.
175.
Gumaa SA, Abu-Samra MT. 1981. Experimental mycetoma infection in the goat. J Comp Pathol 91:341–346.
176.
Mahgoub ES. 1978. Experimental infection of athymic nude New Zealand mice, nu nu strain with mycetoma agents. Sabouraudia 16:211–216.
177.
Nyuykonge B, Klaassen CHW, Zandijk WHA, de Hoog GS, Ahmed SA, Desnos-Ollivier M, Verbon A, Bonifaz A, van de Sande WWJ. 2020. Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico. J Eur Acad Dermatol Venereol 34:1828–1834.
178.
Siddig EE, Nyuykonge B, Mhmoud NA, Abdallah OB, Bahar MEN, Ahmed ES, Nyaoke B, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ. 2023. Comparing the performance of the common used eumycetoma diagnostic tests. Mycoses 66:420–429.
179.
Emery D, Denning DW. 2020. The global distribution of actinomycetoma and eumycetoma. PLoS Negl Trop Dis 14:e0008397.
180.
van de Sande WWJ, Maghoub ES, Fahal AH, Goodfellow M, Welsh O, Zijlstra E. 2014. The mycetoma knowledge gap: identification of research priorities. PLoS Negl Trop Dis 8:e2667.
181.
Ganawa ETS, Bushara MA, Musa AEA, Bakhiet SM, Fahal AH. 2021. Mycetoma spatial geographical distribution in the Eastern Sennar locality, Sennar state, Sudan. Trans R Soc Trop Med Hyg 115:375–382.
182.
Ajello L. 1962. Epidemiology of human fungus infections, p 69–83. In Dalldorf G (ed), Fungi and fungous diseases. Charles C Thomas Springfield, Illinois.
183.
Baylet R, Camain R, Rey M. 1961. Champignons de mycétomes isolés des épineux au Sénégal. Bull Soc Med Afr Noire Lang Fr 6:317–319.
184.
Emmons CW. 1962. Soil reservoirs of pathogenic fungi. J Wash Acad Sci 52:3–9.
185.
Mackinnon JE, Conti-Diaz IA, Gezuele E, Civila E. 1971. Datos sobre ecologia de Allescheria boydii, Shear. Shear. Rev Urug Pathol Clin Microbiol 9:37–43.
186.
Segretain G. 1972. Recherches sur l’écologie de Madurella mycetomi au Senegal. Bull Soc Fr Mycol Med 14:121–124.
187.
Thirumalachar MJ, Padhye AA. 1968. Isolation of Madurella mycetomi from soil in India. Hindustan Antibiot Bull 10:314–318.
188.
Segretain G, Destombes P. 1961. Description d’un nouvel agent de maduromycose Neotestudina rosatii, n. gen., n. sp. isolé en Afrique. C R Hebd Seances Acad Sci 253:2577–2579.
189.
Segretain G, Mariat F. 1968. echerches sur la presence d’agents de mycetomes dans le sol et sur les épineux du Senegal et de la Mauritanie. Bull Soc Pathol Exot Filiales 61:194–202.
190.
Nyuykonge B, Siddig EE, Konings M, Bakhiet S, Verbon A, Klaassen CHW, Fahal AH, van de Sande WWJ. 2022. Madurella mycetomatis grains within a eumycetoma lesion are clonal. Med Mycol 60:myac051.
191.
van de Sande WWJ, de Kat J, Coppens J, Ahmed AOA, Fahal A, Verbrugh H, van Belkum A. 2007. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 9:1114–1123.
192.
Lim W, Konings M, Parel F, Eadie K, Strepis N, Fahal A, Verbon A, van de Sande WWJ. 2022. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella. Med Mycol 60:myac003.
193.
van de Sande WWJ, Fahal AH, Goodfellow M, Mahgoub ES, Welsh O, Zijlstra EE. 2014. Merits and pitfalls of the currently used diagnostic tools in mycetoma. PLoS Negl Trop Dis 8:e2918.
194.
Sheehan G, Konings M, Lim W, Fahal A, Kavanagh K, van de Sande WWJ. 2020. Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae. PLoS Negl Trop Dis 14:e0008190.
195.
Geneugelijk K, Kloezen W, Fahal AH, van de Sande WWJ. 2014. Active matrix metalloprotease-9 is associated with the collagen capsule surrounding the Madurella mycetomatis grain in mycetoma. PLoS Negl Trop Dis 8:e2754.
196.
de Klerk N, de Vogel C, Fahal A, van Belkum A, van de Sande WWJ. 2012. Fructose-bisphosphate aldolase and pyruvate kinase, two novel immunogens in Madurella mycetomatis. Med Mycol 50:143–151.
197.
van de Sande WWJ, Janse D-J, Hira V, Goedhart H, van der Zee R, Ahmed AOA, Ott A, Verbrugh H, van Belkum A. 2006. Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol 177:1997–2005.
198.
Litvintseva AP, Bakhiet S, Gade L, Wagner DD, Bagal UR, Batra D, Norris E, Rishishwar L, Beer KD, Siddig EE, Mhmoud NA, Chow NA, Fahal A. 2022. Genomics and metagenomics of Madurella mycetomatis, a causative agent of black grain mycetoma in Sudan. PLoS Negl Trop Dis 16:e0010787.
199.
Abugessaisa I, Konings M, Manabe R-I, Kawashima T, Hasegawa A, Takahashi C, Tagami M, Okazaki Y, Lim W, Verbon A, Fahal AH, Kasukawa T, van de Sande WWJ. 2023. Iron regulatory pathways differentially expressed during Madurella mycetomatis grain development in Galleria mellonella. bioRxiv.
200.
Segretain G, Destombes P. 1969. Recherches sur mycetomes à Madurella grisea et Pyrenochaeta romeroi. Sabouraudia 7:51–61.
201.
Chandler FW, Ajello L. 1997. Mycetoma, chapter 113, p 1035–1044. In Connor DH, Schwartz DA, Lack EE, Manz H, Lack E, Chandler FW (ed), Pathology of infectious diseases. Appleton & Lange, Stamford, CT.
202.
CDC. 2022. Public health imagge library record 21194, on centers for disease control and prevention. Available from: https://phil.cdc.gov/Details.aspx?pid=21194. Retrieved 10 Feb 2023.
203.
Al‐Hatmi AMS, Bonifaz A, Tirado‐Sánchez A, Meis JF, de Hoog GS, Ahmed SA. 2017. Fusarium species causing eumycetoma: report of two cases and comprehensive review of the literature . Mycoses 60:204–212.
204.
Ellis D. Trematosphaeria grisea. University of Adelaide. Available from: https://www.adelaide.edu.au/mycology/fungal-descriptions-and-antifungal-susceptibility/hyphomycetes-conidial-moulds/trematosphaeria . Accessed 8 December 2023
205.
Kwon-Chung KJ, Bennet JE. 1992. Medical mycology. Lea and Febiger, Philadelphia.
206.
Verghese A, Klokke AH. 1966. Histologic diagnosis of species of fungus causing mycetoma. Indian J Med Res 54:524–530.
207.
Destombes P. 1964. Histologic structure of mycetomas. Ann Soc Belges Med Trop Parasitol Mycol 44:897–908.
208.
Hay RJ, Collins MJ. 1983. An ultrastructural study of pale eumycetoma grains. Sabouraudia 21:261–269.
209.
Hay RJ, Mackenzie DWR. 1982. The histopathological features of pale grain eumycetoma. Trans R Soc Trop Med Hyg 76:839–844.
210.
Ma J, Konings M, Verbon A, van de Sande WWJ. 2023. A Falciformispora senegalensis grain model in Galleria mellonella larvae. Med Mycol 61:myad070.
211.
Rao VK, Prasad CR. 1973. Experimental maduromycosis. I. Infection of mice with Phialophora jeanselmei. Mycopathol Mycol Appl 51:119–126.
212.
Avram A. 1967. Experimental induction of grains with Cephalosporium falciforme. Med Mycol 5:89–91.
213.
Ma J, Konings M, Verbon A, van de Sande WWJ. 2023. A Falciformispora senegalensis grain model in Galleria mellonella larvae. Med Mycol 61:myad070.
214.
Fahal AH, Suliman SH, Hay R. 2018. Mycetoma: the spectrum of clinical presentation. Trop Med Infect Dis 3:97.
215.
Fahal A, Mahgoub ES, El Hassan AM, Abdel-Rahman ME. 2015. Mycetoma in the Sudan: an update from the mycetoma research centre. PLoS Negl Trop Dis 9:e0003679.
216.
Fahal AH, Suliman SH, Gadir AF, el Hag IA, el Amin FI, Gumaa SA, Mahgoub ES. 1994. Abdominal wall mycetoma: an unusual presentation. Trans R Soc Trop Med Hyg 88:78–80.
217.
Abd El Bagi ME. 2003. New radiographic classification of bone involvement in pedal mycetoma. AJR Am J Roentgenol 180:665–668.
218.
Siddig EE, Mhmoud NA, Bakhiet SM, Abdallah OB, Mekki SO, El Dawi NI, Van de Sande W, Fahal AH. 2019. The accuracy of histopathological and cytopathological techniques in the identification of the mycetoma causative agents. PLoS Negl Trop Dis 13:e0007056.
219.
Chen SC-A, Halliday CL, Hoenigl M, Cornely OA, Meyer W. 2021. Scedosporium and Lomentospora infections: contemporary microbiological tools for the diagnosis of invasive disease. J Fungi 7:23.
220.
Ahmed SA, van de Sande WWJ, Stevens DA, Fahal A, van Diepeningen AD, Menken SBJ, de Hoog GS. 2014. Revision of agents of black-grain eumycetoma in the order Pleosporales. Persoonia 33:141–154.
222.
Singh A, Singh PK, Kumar A, Chander J, Khanna G, Roy P, Meis JF, Chowdhary A. 2017. Molecular and matrix-assisted laser desorption ionization-time of flight mass spectrometry-based characterization of clinically significant melanized fungi in India. J Clin Microbiol 55:1090–1103.
223.
Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, Ranque S. 2011. Pseudallescheria/Scedosporium complex species identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Med Mycol 49:621–626.
224.
Ahmed A, Desplaces N, de Hoog S, Verbrugh H, van Belkum A. 2003. Eumycetoma caused by Madurella mycetomatis identified by PCR and sequencing: a report of two cases. J Clin Microbiol 41:1813–1816.
225.
Lim W, Siddig E, Eadie K, Nyuykonge B, Ahmed S, Fahal A, Verbon A, Smit S, van de Sande WW. 2020. The development of a novel diagnostic PCR for Madurella mycetomatis using a comparative genome approach. PLoS Negl Trop Dis 14:e0008897.
226.
Arastehfar A, Lim W, Daneshnia F, van de Sande WWJ, Fahal AH, Desnos-Ollivier M, de Hoog GS, Boekhout T, Ahmed SA. 2020. Madurella real-time PCR, a novel approach for eumycetoma diagnosis. PLoS Negl Trop Dis 14:e0007845.
227.
Hashizume H, Taga S, Sakata MK, Hussein M, Siddig EE, Minamoto T, Fahal AH, Kaneko S. 2023. Environmental detection of eumycetoma pathogens using multiplex real-time PCR for soil DNA in Sennar state, Sudan. Trop Med Health 51:71.
228.
Lu Q, Gerrits van den Ende AHG, Bakkers JMJE, Sun J, Lackner M, Najafzadeh MJ, Melchers WJG, Li R, de Hoog GS. 2011. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J Clin Microbiol 49:960–967.
229.
Ahmed SA, van den Ende BHGG, Fahal AH, van de Sande WWJ, de Hoog GS. 2014. Rapid identification of black grain eumycetoma causative agents using rolling circle amplification. PLoS Negl Trop Dis 8:e3368.
230.
Lackner M, Najafzadeh MJ, Sun J, Lu Q, Hoog GS de. 2012. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl Environ Microbiol 78:126–133.
231.
Welsh O, Al-Abdely HM, Salinas-Carmona MC, Fahal AH. 2014. Mycetoma medical therapy. PLoS Negl Trop Dis 8:e3218.
232.
Milani B, Dagne DA, Choi HL, Schito M, Stone HA. 2023. Diagnostic capacities and treatment practices on implantation mycoses: results from the 2022 WHO global online survey. PLoS Negl Trop Dis 17:e0011443.
233.
Mattioni S, Develoux M, Brun S, Martin A, Jaureguy F, Naggara N, Bouchaud O. 2013. Management of mycetomas in France. Med Mal Infect 43:286–294.
234.
Anonymous. 2017. Proof-of-concept superiority trial of fosravuconazole versus itraconazole for eumycetoma in Sudan. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/study/NCT03086226. Retrieved 8 Dec 2023.
235.
van de Sande WWJ. 2021. In vitro susceptibility testing for black grain eumycetoma causative agents. Trans R Soc Trop Med Hyg 115:343–354.
236.
Ahmed AOA, van de Sande WWJ, van Vianen W, van Belkum A, Fahal AH, Verbrugh HA, Bakker-Woudenberg IAJM. 2004. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 48:2742–2746.
237.
Ahmed SA, Kloezen W, Duncanson F, Zijlstra EE, de Hoog GS, Fahal AH, van de Sande WWJ. 2014. Madurella mycetomatis is highly susceptible to ravuconazole. PLoS Negl Trop Dis 8:e2942.
238.
Kloezen W, Meis JF, Curfs-Breuker I, Fahal AH, van de Sande WWJ. 2012. In vitro antifungal activity of isavuconazole to Madurella mycetomatis. Antimicrob Agents Chemother 56:6054–6056.
239.
Lim W, Eadie K, Konings M, Rijnders B, Fahal AH, Oliver JD, Birch M, Verbon A, van de Sande W. 2020. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. J Antimicrob Chemother 75:936–941.
240.
van Belkum A, Fahal AH, van de Sande WWJ. 2011. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 55:1771–1773.
241.
van de Sande WWJ, Fahal AH, Bakker-Woudenberg IAJM, van Belkum A. 2010. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother 54:2738–2740.
242.
van de Sande WWJ, Luijendijk A, Ahmed AOA, Bakker-Woudenberg IAJM, van Belkum A. 2005. Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5 [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob Agents Chemother 49:1364–1368.
243.
Ahmed SA, de Hoog GS, Stevens DA, Fahal AH, van de Sande WWJ. 2015. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. Med Mycol 53:295–301.
244.
Nyuykonge B, Croughs PD, Fahal AH, Verbon A, van de Sande WWJ. 2019. Pyomelanin secretion in Madurella mycetomatis interferes with spectrophotometric endpoint reading using the sensititre YeastOne alamarBlue assay but not with visual endpoint reading. Antimicrob Agents Chemother 64:e01532-19.
245.
Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL. 2008. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 61:805–809.
246.
Nyuykonge B, Siddig EE, Mhmoud NA, Nyaoke BA, Zijlstra EE, Verbon A, Bakhiet S, Fahal AH, van de Sande WWJ. 2022. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma. Mycoses 65:1170–1178.
247.
Nyuykonge B, Lim W, van Amelsvoort L, Bonifaz A, Fahal A, Badali H, Abastabar M, Verbon A, van de Sande W. 2022. Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole. Mycoses 65:650–655.
248.
Pfaller MA, Carvalhaes CG, Castanheira M. 2023. Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY antifungal surveillance program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity. Mycoses 66:854–868.
249.
Gilgado F, Serena C, Cano J, Gené J, Guarro J. 2006. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 50:4211–4213.
250.
Pfaller MA, Carvalhaes CG, Messer SA, Rhomberg PR, Castanheira M. 2021. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. Diagn Microbiol Infect Dis 101:115473.
251.
Guarro J, Soler L, Rinaldi MG. 1995. Pathogenicity and antifungal susceptibility of Chaetomium species. Eur J Clin Microbiol Infect Dis 14:613–618.
252.
Wildfeuer A, Seidl HP, Paule I, Haberreiter A. 1998. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41:309–319.
253.
Pfaller MA, Messer SA, Hollis RJ, Jones RN, Group SP. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 46:1032–1037.
254.
Ryder NS. 1999. Activity of terbinafine against serious fungal pathogens. Mycoses 42 Suppl 2:115–119.
255.
Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 37:1606–1609.
256.
Alastruey-Izquierdo A, Cuesta I, Houbraken J, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. 2010. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med Mycol 48:97–102.
257.
Badali H, de Hoog GS, Curfs-Breuker I, Klaassen CHW, Meis JF. 2010. Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility. J Clin Microbiol 48:2350–2356.
258.
Wang Q, Wang L, Lian L, Pu X, Tang L, Li Y, Liu Y. 2023. Case report: a case of ocular infection caused by Corynespora cassiicola. Front Cell Infect Microbiol 13:1160831.
259.
da Cunha Keith C, Sutton DA, Fothergill AW, Gené J, Cano J, Madrid H, Hoog S de, Crous PW, Guarro J. 2013. In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia. Diagn Microbiol Infect Dis 76:168–174.
260.
Gülmez D, Doğan Ö, Boral B, Döğen A, İlkit M, de Hoog GS, Arikan-Akdagli S. 2018. In vitro activities of antifungal drugs against environmental Exophiala isolates and review of the literature. Mycoses 61:561–569.
261.
Ng CY, de Hoog S, Li H-E, Lee Y-Y, Chen C-B, Sun P-L. 2017. Cutaneous Exophiala oligosperma infection in a patient with bullous pemphigoid with a review of the literature. Mycopathologia 182:539–547.
262.
da Cunha KC, Sutton DA, Gené J, Capilla J, Cano J, Guarro J. 2012. Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother 56:4951–4954.
263.
Sekhon AS, Padhye AA, Garg AK, Ahmad H, Moledina N. 1994. In vitro sensitivity of medically significant Fusarium species to various antimycotics. Chemotherapy 40:239–244.
264.
Kawakami H, Inuzuka H, Hori N, Takahashi N, Ishida K, Mochizuki K, Ohkusu K, Muraosa Y, Watanabe A, Kamei K. 2015. Inhibitory effects of antimicrobial agents against Fusarium species. Med Mycol 53:603–611.
265.
Azor M, Gené J, Cano J, Sutton DA, Fothergill AW, Rinaldi MG, Guarro J. 2008. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother 52:2228–2231.
266.
Aneke CI, Rhimi W, Hubka V, Otranto D, Cafarchia C. 2021. Virulence and antifungal susceptibility of Microsporum canis strains from animals and humans. Antibiotics (Basel) 10:296.
267.
Kano R, Watanabe M, Tsuchihashi H, Ogawa T, Ogawa Y, Komiyama E, Hirasawa Y, Hiruma M, Ikeda S. 2023. Antifungal susceptibility testing for Microsporum canis from cats in Japan. Med Mycol J 64:19–22.
268.
Lacroix C, de Chauvin MF. 2008. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. J Antimicrob Chemother 61:835–837.
269.
Castelli MV, Alastruey-Izquierdo A, Cuesta I, Monzon A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. 2008. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother 52:2926–2928.
270.
Badali H, Khodavaisy S, Fakhim H, de Hoog GS, Meis JF, Chowdhary A. 2015. In vitro susceptibility profiles of eight antifungal drugs against clinical and environmental strains of Phaeoacremonium. Antimicrob Agents Chemother 59:7818–7822.
271.
Li Y, Wan Z, Li R. 2014. In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa. Antimicrob Agents Chemother 58:5609–5612.
272.
Yao L, Wang H, Wan Z, Li R, Yu J. 2019. The high diversity and variable susceptibility of clinically relevant Acremonium-like species in China. Mycopathologia 184:759–773.
273.
Deng S, Zhang C, Seyedmousavi S, Zhu S, Tan X, Wen Y, Huang X, Lei W, Zhou Z, Fang W, Shen S, Deng D, Pan W, Liao W. 2015. Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum. Antimicrob Agents Chemother 59:4312–4314.
274.
Singh J, Zaman M, Gupta AK. 2007. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 45:595–602.
275.
Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24–34.
276.
Murray IG, Colichon H. 1962. Chemotherapy of maduromycosis. I. Preliminary experiments with diamidinodi-phenylamine dihydrochloride and amphotericin B in vivo and in vitro. Trans R Soc Trop Med Hyg 56:156–165.
277.
Gao L, Jiang S, Sun Y, Deng M, Wu Q, Li M, Zeng T. 2016. Evaluation of the effects of photodynamic therapy alone and combined with standard antifungal therapy on planktonic cells and biofilms of Fusarium spp. and Exophiala spp. Front Microbiol 7:617.
278.
Sun Y, Gao L, He C, Li M, Zeng T. 2018. In vitro interactions between IAP antagonist AT406 and azoles against planktonic cells and biofilms of pathogenic fungi Candida albicans and Exophiala dermatitidis. Med Mycol 56:1045–1049.
279.
Kloezen W, Parel F, Brüggemann R, Asouit K, Helvert-van Poppel M, Fahal A, Mouton J, van de Sande W. 2018. Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis. Med Mycol 56:469–478.
280.
van de Sande WWJ, van Vianen W, ten Kate M, Fahal A, Bakker-Woudenberg I. 2015. Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice. Br J Dermatol 173:1561–1562.
281.
Zein HAM, Fahal AH, Mahgoub ES, El Hassan TA, Abdel-Rahman ME. 2012. Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the mycetoma research centre, University of Khartoum, Sudan. Trans R Soc Trop Med Hyg 106:639–644.
282.
Musa EA, Abdoon IH, Bakhiet SM, Osman B, Abdalla SA, Fahal AH. 2023. Mycetoma management and clinical outcomes: the mycetoma research center experience. Trans R Soc Trop Med Hyg 117:12–21.
283.
Vilela R, Duarte OMV, Rosa CA, Castro JGF, Lyon S, Motta RL, Moura ACL. 2004. A case of eumycetoma due to Madurella grisea in northern Brazil. Mycopathologia 158:415–418.
284.
Machado LA, Rivitti MC, Cucé LC, Salebian A, Lacaz C da S, Heins-Vaccari EM, Belda Júnior W, de Melo NT. 1992. Black-grain eumycetoma due to Madurella grisea. A report of 2 cases. Rev Inst Med Trop Sao Paulo 34:569–580.
285.
Belda Junior W, Cuce LC, Dias MC, Lacaz Cda S. 1989. Eumicetoma de graos pretos por Madurella grisea. Rev Inst Med Trop Sao Paulo 31:195–199.
286.
Sampaio FMS, Wanke B, Freitas DFS, Coelho JMC de O, Galhardo MCG, Lyra MR, Lourenço MC da S, Paes R de A, do Valle ACF. 2017. Review of 21 cases of mycetoma from 1991 to 2014 in Rio de Janeiro, Brazil. PLoS Negl Trop Dis 11:e0005301.
287.
Mahgoub ES, Gumaa SA. 1984. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 78:376–379.
288.
Fahal AH, Rahman IA, El-Hassan AM, Rahman MEAEL, Zijlstra EE. 2011. The safety and efficacy of Itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105:127–132.
289.
Samy AM, van de Sande WWJ, Fahal AH, Peterson AT. 2014. Mapping the potential risk of mycetoma infection in Sudan and South Sudan using ecological niche modeling. PLoS Negl Trop Dis 8:e3250.
290.
Hassan R, Simpson H, Cano J, Bakhiet S, Ganawa E, Argaw D, Newport MJ, Deribe K, Fahal AH. 2021. Modelling the spatial distribution of mycetoma in Sudan. Trans R Soc Trop Med Hyg 115:1144–1152.
291.
Fahal AH, Bakhiet SM. 2023. Mycetoma and the environment. PLoS Negl Trop Dis 17:e0011736.
292.
Hounsome N, Hassan R, Bakhiet SM, Deribe K, Bremner S, Fahal AH, Newport MJ. 2022. Role of socioeconomic factors in developing mycetoma: results from a household survey in Sennar state. PLoS Negl Trop Dis 16:e0010817.
293.
Hassan R, Deribe K, Simpson H, Bremner S, Elhadi O, Alnour M, Fahal AH, Newport M, Bakhiet S. 2022. Individual risk factors of mycetoma occurrence in Eastern Sennar locality, Sennar state, Sudan: a case-control study. TropicalMed 7:174.
294.
Bakhiet SM, Fahal AH, Musa AM, Mohamed ESW, Omer RF, Ahmed ES, El Nour M, Mustafa ERM, Sheikh A Rahman ME, Suliman SH, El Mamoun MAG, El Amin HM. 2018. A holistic approach to the mycetoma management. PLoS Negl Trop Dis 12:e0006391.
295.
Azrag RS, Bakhiet SM, Mhmoud NA, Almalik AM, Mohamed AH, Fahal AH. 2021. A possible role for ticks in the transmission of Madurella mycetomatis in a mycetoma-endemic village in Sudan . Trans R Soc Trop Med Hyg 115:364–374.

Author Bios

Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
Wendy van de Sande is an associate professor in medical mycology at ErasmusMC, the Netherlands. She has been studying mycetoma since 2001 and obtained her PhD from Erasmus University in Rotterdam in 2007 cumlaude. She published 128 peer-reviewed papers on mycetoma. She and her team developed several diagnostic tools to identify the causative agents at the species level. These tools are currently used worldwide. She also leads the biological screening in the Mycetoma Open Source drug discovery program MycetOS. She is a founding member of the global mycetoma working group, convener of the eumycetoma working group at the International Society of Human and Animal Mycoses and vice chair of the skinNTD subgroup of the Diagnostic Technical Advisory Group of the World Health Organization.
The Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan
Prof. Ahmed Fahal, a distinguished surgeon and professor, has significantly contributed to medical research, education, and the management of mycetoma. Trained at the University of Khartoum and in the UK, he attained the position of consultant surgeon at Soba University Hospital and a professorship at the University of Khartoum. He excels in mycetoma and tropical surgery, founding the globally recognized Mycetoma Research Centre at the University of Khartoum, WHO Collaborating Center on Mycetoma and Skin NTDs. His extensive research, with over 300 peer-reviewed articles, positions him among the top 2% of global scientists. Playing fundamental roles in educational development and scientific research agencies, he currently serves as the Vice President of the Arab Scientific Research Councils Federation. Prof. Fahal's enduring legacy encompasses groundbreaking clinical trials, the establishment of mycetoma satellite centers, and vocational training for mycetoma patients, reflecting his dedication to comprehensive healthcare. His numerous awards underscore his outstanding achievements in scientific innovation and research.

Information & Contributors

Information

Published In

cover image Clinical Microbiology Reviews
Clinical Microbiology Reviews
Volume 37Number 213 June 2024
eLocator: e00034-23
Editor: Graeme N. Forrest, Rush University, Chicago, Illinois, USA
PubMed: 38690871

History

Published online: 1 May 2024

Permissions

Request permissions for this article.

Keywords

  1. mycetoma
  2. diagnosis
  3. susceptibility
  4. itraconazole
  5. biofilm
  6. grain
  7. neglected tropical disease
  8. molecular diagnostics

Contributors

Authors

Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
The Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan

Editor

Graeme N. Forrest
Editor
Rush University, Chicago, Illinois, USA

Reviewers

Rod Hay
Ad Hoc Peer Reviewer
The International Foundation for Dermatology, London, United Kingdom
Ferry Hagen
Ad Hoc Peer Reviewer
Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands

Notes

The authors declare no conflict of interest.

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Get Access

LOGIN OPTIONS
Non-Member Login
Buy Article
Clinical Microbiology Reviews Vol.37 • Issue 2 • ASM Journals Pay Per View, PPV 25
Journal Subscription
Clinical Microbiology Reviews
ASM members can purchase subscriptions to journals.
Join or renew

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Get Access

LOGIN OPTIONS
Non-Member Login
Buy Article
Clinical Microbiology Reviews Vol.37 • Issue 2 • ASM Journals Pay Per View, PPV 25
Journal Subscription
Clinical Microbiology Reviews
ASM members can purchase subscriptions to journals.
Join or renew

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy